IRIS
DAGNA, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.303
AS - Asia 10.130
NA - Nord America 9.775
SA - Sud America 2.174
AF - Africa 228
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 1
Totale 35.661
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.278
RU - Federazione Russa 7.047
SG - Singapore 3.579
CN - Cina 3.296
BR - Brasile 1.769
IT - Italia 1.468
RO - Romania 1.137
SE - Svezia 1.134
HK - Hong Kong 1.100
VN - Vietnam 903
DE - Germania 640
FR - Francia 509
GB - Regno Unito 387
CA - Canada 256
BD - Bangladesh 249
IN - India 242
FI - Finlandia 235
AR - Argentina 175
NL - Olanda 156
MX - Messico 146
AT - Austria 115
PL - Polonia 115
JP - Giappone 111
TR - Turchia 100
ZA - Sudafrica 92
ID - Indonesia 89
ES - Italia 81
IQ - Iraq 67
EC - Ecuador 57
IE - Irlanda 54
PK - Pakistan 53
PH - Filippine 46
CO - Colombia 45
UA - Ucraina 40
LT - Lituania 39
VE - Venezuela 37
MA - Marocco 35
MY - Malesia 34
SA - Arabia Saudita 30
AU - Australia 29
AE - Emirati Arabi Uniti 28
PY - Paraguay 27
UZ - Uzbekistan 27
PE - Perù 25
CL - Cile 23
EG - Egitto 22
IL - Israele 22
BE - Belgio 21
NP - Nepal 21
TN - Tunisia 20
IR - Iran 19
JM - Giamaica 19
KE - Kenya 19
JO - Giordania 18
HN - Honduras 16
DO - Repubblica Dominicana 15
NO - Norvegia 13
CH - Svizzera 11
GR - Grecia 11
MD - Moldavia 11
UY - Uruguay 11
AZ - Azerbaigian 10
DZ - Algeria 10
NI - Nicaragua 10
PT - Portogallo 10
BG - Bulgaria 9
KR - Corea 9
TH - Thailandia 9
BH - Bahrain 8
HU - Ungheria 8
KZ - Kazakistan 8
NZ - Nuova Zelanda 8
SN - Senegal 8
CZ - Repubblica Ceca 7
PA - Panama 7
XK - ???statistics.table.value.countryCode.XK??? 7
DK - Danimarca 6
LV - Lettonia 6
TW - Taiwan 6
BW - Botswana 5
EU - Europa 5
GE - Georgia 5
GT - Guatemala 5
LU - Lussemburgo 5
MK - Macedonia 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
ET - Etiopia 4
LB - Libano 4
OM - Oman 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
AL - Albania 3
HR - Croazia 3
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
MO - Macao, regione amministrativa speciale della Cina 3
Totale 35.605
Salva come PNG Salva come JPEG
Città #
Dallas 2.481
Singapore 1.758
Moscow 1.399
Ashburn 1.204
San Jose 1.085
Hong Kong 1.074
Shanghai 655
New York 458
Beijing 455
Hefei 436
Milan 376
Lauterbourg 374
Ho Chi Minh City 327
Lawrence 278
Princeton 278
Los Angeles 276
Munich 197
Hanoi 193
Boardman 185
São Paulo 178
Nuremberg 152
Santa Clara 137
Helsinki 128
Rome 115
Orem 114
Warsaw 93
Denver 88
Montreal 88
London 83
Tokyo 74
Atlanta 70
Brooklyn 69
Guangzhou 69
Poplar 69
Rio de Janeiro 69
Chennai 63
Frankfurt am Main 62
Johannesburg 61
Chicago 57
Mexico City 57
Turku 54
Amsterdam 52
Council Bluffs 52
Phoenix 50
Seattle 50
Dublin 49
Lappeenranta 49
Toronto 49
Houston 48
Boston 46
Stockholm 46
Manchester 44
Pune 43
Ankara 42
Vienna 42
Washington 39
Da Nang 37
Mumbai 36
Belo Horizonte 35
Buffalo 33
Falkenstein 33
Haiphong 33
Brasília 30
Cesano Boscone 30
Tianjin 27
Querétaro 26
San Francisco 25
Shenzhen 25
Istanbul 24
Tashkent 24
The Dalles 24
Xi'an 24
Ancona 23
Curitiba 23
Jakarta 22
Lahore 22
New Delhi 22
Florence 21
Salvador 21
Campinas 20
Hải Dương 20
Turin 20
Cape Town 19
Charlotte 19
City of London 19
Porto Alegre 19
Baghdad 18
Bologna 18
Changsha 18
Genoa 18
Hangzhou 18
Kuala Lumpur 18
Bexley 17
Biên Hòa 17
Brussels 17
Columbus 17
Paris 17
Wolfhagen 17
Amman 16
Guayaquil 16
Totale 17.138
Salva come PNG Salva come JPEG
Nome #
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study 569
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 457
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 435
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 388
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 346
The association between body mass index and fibromyalgia severity: Data from a cross-sectional survey of 2339 patients 333
Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study 254
Monkeypox in a patient with undifferentiated connective tissue disease 250
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 230
Heart Rate Variability in Subjects with Severe Allergic Background Undergoing COVID-19 Vaccination 209
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 206
Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry 205
EA4HP24-LYWS-293 An indolent EBV-related clonal T-cell proliferation presenting as chronic rhinosinusitis 193
A radiological predictor for pneumomediastinum/pneumothorax in COVID-19 ARDS patients 181
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 177
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 172
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency 171
A subset of CD4+CD8α- Cytotoxic T cells is expanded in patients with IgG4-Related type 1 autoimmune pancreatitis and decreases with glucocorticoid treatment 169
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 168
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 160
IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients 159
Gas-exchange deficit and systemic hypoperfusion in COVID-19 and non-COVID-19 young adult patients with pneumonia 154
Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy 153
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 151
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 149
Two-year multidisciplinary follow-up of COVID-19 patients requiring invasive and noninvasive respiratory support 149
Virus-encoded chemokines, chemokine receptors and chemokine-binding proteins: new paradigms for future therapy 146
Biobanking for COVID-19 research 145
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 145
A CD8α− Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment 137
Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome 136
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) 136
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 133
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 132
Anakinra for patients with COVID-19: an updated systematic review and meta-analysis 131
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 131
Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature 129
Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease 129
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 127
A cd8 alpha-negative subset of cd4+slamf7+ cytotoxic t cells is expanded in patients with igg4-related disease and decreases following glucocorticoid treatment 127
Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients 126
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 125
A bitter effect: thrombocytopenia induced by a quinidine-containing beverage 124
Pentraxin-3 as a Marker of Disease Activity in Takayasu Arteritis 124
Post-traumatic stress disorder in patients with systemic lupus erythematosus heavily affects quality of life. A cross-sectional web survey-based study 123
Association of autoimmune pancreatitis and intraductal papillary mucinous neoplasm. A retrospective analysis from a tertiary care referral center 123
Beyond Neuropsychiatric Manifestations of Systemic Lupus Erythematosus: Focus on Post-traumatic Stress Disorder and Alexithymia 122
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 121
One-Year Multidisciplinary Follow-Up of Patients With COVID-19 Requiring Invasive Mechanical Ventilation 121
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 120
Interactions between Severe Allergy and Anxiety in Anti-SARS-CoV-2 Vaccinees 119
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 119
[Cardiovascular involvement in Erdheim-Chester syndrome: clinical and therapeutic implications]. FT Coinvolgimento cardiovascolare nella sindrome di Erdheim-Chester: aspetti clinici e terapeutici. 119
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro 119
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 119
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 119
Prone positioning in awake COVID-19 patients: a systematic review and meta-analysis 118
Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine 118
3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target 117
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 116
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 116
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 115
Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy 115
A Novel Histiocytosis With Synovial and Skin Involvement 115
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 115
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 114
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 114
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 113
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 113
Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life 113
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 113
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry 111
Igg4-related disease of the oral cavity. Case series from a large single-center cohort of italian patients 111
C3-glomerulopathy and MGUS: The skin beyond the kidney 111
La misurazione quantitativa dell’uptake di 18F-FDG in TC/PET riflette l’espansione dei plasmablasti circolanti nella malattia IgG4 correlata 111
Therapeutic strategies for primary heart involvement in systemic sclerosis 110
A Multinational Survey Investigating the Unmet Needs and Patient Perspectives Concerning Proton Pump Inhibitors in Systemic Sclerosis 110
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort 110
Diamine Oxidase Supplementation in Chronic Spontaneous Urticaria: A Randomized, Double-Blind Placebo-Controlled Study 110
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 109
Case report: Successful use of mepolizumab for immune checkpoint inhibitors–induced hypereosinophilic syndrome in two patients with solid malignancies 108
Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis 107
Two months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study 107
Drug retention rates of biological agents in adult onset Still's disease 107
Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study 106
Testosterone in males with COVID-19: A twelve-month cohort study 106
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 106
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 106
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 105
Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients 105
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 104
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 103
Association of IgG4-related disease and systemic rheumatic disorders 103
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 103
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 103
Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes 103
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 103
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 103
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study 102
A relapsing inflammatory syndrome and HHV-8 102
Totale 14.825
Salva come PNG Salva come JPEG
Categoria #
all - tutte 190.836
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 190.836
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 0 4
2021/2022431 3 0 101 78 26 27 33 26 42 37 30 28
2022/20232.175 652 435 141 21 36 244 220 209 102 39 40 36
2023/20242.244 79 135 231 200 184 373 118 204 18 92 210 400
2024/20257.670 639 146 220 243 291 550 2.019 711 1.014 686 486 665
2025/202623.750 1.583 2.171 2.331 2.866 1.780 662 2.025 1.662 6.132 1.253 731 554
Totale 36.498